In‐hospital course of patients with heart failure with improved ejection fraction in the <scp>DELIVER</scp> trial
Among patients hospitalized for HF in DELIVER, those with HFimpEF experienced a more adverse in-hospital clinical course, necessitating higher resource utilization beyond standard diuretic therapy compared with patients with HF and LVEF consistently >40%, but had similar in-hospital mortality. Treatment benefits of dapagliflozin were not modified by hospitalization type.
Authors
- Silvio E. Inzucchi
- Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
- Brian Lee Claggett (ORCID: https://orcid.org/0000-0002-4215-9218)
- Maria A. Pabón (ORCID: https://orcid.org/0000-0003-1883-0654)
- Adrian F. Hernandez (ORCID: https://orcid.org/0000-0003-3387-9616)
- Orly Vardeny (ORCID: https://orcid.org/0000-0002-6387-1351)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Safia Chatur (ORCID: https://orcid.org/0009-0004-0082-8649)
- Rudolf A. de Boer (ORCID: https://orcid.org/0000-0002-4775-9140)
- Pablo-Miki Martí Castellote (ORCID: https://orcid.org/0000-0003-0252-5831)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Carolyn S.P. Lam (ORCID: https://orcid.org/0000-0003-1903-0018)
- Mikhail Kosiborod
- Scott D. Solomon
- Akshay S. Desai
- Felipe Martínez
- Sara Siqueira
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- University of Minnesota (US)
- University Medical Center Groningen (NL)
- Harvard University (US)
- National University of Singapore (SG)
- Universidad Nacional de Córdoba (AR)
- British Heart Foundation (GB)
- Yale University (US)
- National University Heart Centre Singapore (SG)
- Minneapolis VA Health Care System (US)
- Duke Medical Center (US)
- Saint Luke's Hospital (US)
- National Heart Centre Singapore (SG)
- University of Missouri–Kansas City (US)
- University of Glasgow (GB)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1002/ejhf.3410
- Citations
- 9
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.62
Funders
- AstraZeneca